Your browser doesn't support javascript.
loading
Evolución tras la embolización de 100 malformaciones arteriovenosas intracraneales / Progression following the embolisation of 100 intracranial arteriovenous malformations
Angulo-Hervías, E; Crespo-Rodríguez, A. M; Guillén-Subirán, M. E; Izquierdo-Hernández, B; Barrena, M. R; Guelbenzu, S.
Afiliação
  • Angulo-Hervías, E; Hospital Miguel Servet. Zaragoza. España
  • Crespo-Rodríguez, A. M; Hospital Miguel Servet. Zaragoza. España
  • Guillén-Subirán, M. E; Hospital Miguel Servet. Zaragoza. España
  • Izquierdo-Hernández, B; Hospital Miguel Servet. Zaragoza. España
  • Barrena, M. R; Hospital Miguel Servet. Zaragoza. España
  • Guelbenzu, S; Hospital Miguel Servet. Zaragoza. España
Rev. neurol. (Ed. impr.) ; 42(1): 8-16, 1 ene., 2006. ilus, tab
Artigo em Es | IBECS | ID: ibc-043831
Biblioteca responsável: ES1.1
Localização: ES1.1 - BNCS
RESUMEN
Introducción. Analizamos las características, evolución y resultados tras la embolización de 100 malformaciones arteriovenosas (MAV) intracraneales con el objetivo de conseguir la obliteración completa de la MAV, la eliminación de los factores de riesgo vascular asociados y disminuir su tamaño para la efectividad de posteriores tratamientos. Pacientes y métodos. Analizamos las características demográficas y anatómicas de 110 pacientes portadores de MAV durante 13 años, y se realizó una embolización a 100de éstos. Se practicaron 203 sesiones de embolización con una media de 3 embolizaciones/paciente. De las 100 MAV embolizadas, hubo 36 MAV a las que sólo se realizó embolización sin otro tratamiento posterior, a 48 se les realizó radiocirugía postembolización y a los 16 restantes cirugía postembolización. El tipo del material usado fueron agentes embólicos líquidos adhesivos (Hystoacril, Glubran®), agentes embólicos no adhesivos (Onyx) y partículas de polivinil alcohol. Se revisó a los pacientes clínica y arteriográficamente. Resultados. De las 100 MAV embolizadas, hubo una erradicación completa con sólo embolización en 27 MAV (27%). De las48 MAV a las que se les realizó radiocirugía posterior, hubo una obliteración media del 78%. De las 16 MAV a las que se realizó cirugía posterior, hubo una obliteración media del 70%. De las 100MAV embolizadas, hubo 16 en las que quedaron restos. La embolización eliminó la mayoría de los factores de riesgo vascular asociados de 43 MAV con factores de riesgo asociados, desaparecieron en 28 MAV (65%). Con la embolización se produjo una morbilidad del 8% y mortalidad del 2%. Conclusión. La embolización eliminó la mayoría de los factores de riesgo vascular, con una obliteración completa en 27 casos y se redujo el tamaño para posteriores tratamientos de manera satisfactoria, y todo ello con una morbimortalidad aceptable (AU)
ABSTRACT
Introduction. We analysed the characteristics, progression and outcomes observed following the embolisation of 100intracranial arteriovenous malformations (AVM) that were performed in order to achieve complete obliteration of the AVM, the elimination of associated vascular risk factors and also to reduce their size with a view to increasing the effectiveness of later treatments. Patients and methods. The demographic and anatomical characteristics of 110 patients with AVM were analysed over a period of 13 years, and embolisation was performed in 100 of them. In all, 203 embolisation sessions were carried out with an average of 3 embolisations per patient. Of the 100 AVM that were embolised, 36 were AVM which were treated by embolisation with no later therapy, 48 required radiosurgery after the embolisation and the other 16 were submitted to surgery following the embolisation. The type of materials used included liquid adhesive embolic agents (Hystoacryl, Glubran ®), non adhesiveembolic agents (Onyx) and polyvinyl alcohol particles. Patients were examined clinically and arteriographically. Results. Of the 100 AVM that were embolised, complete eradication was accomplished with just embolisation in 27 cases of AVM (27%). Of the 48 AVM in which radiosurgery was carried out at a later date, the average rate of obliteration was 78% and of the 16 AVM in which surgery was carried out some time later, the average rate of obliteration was 70%. Of the 100 AVM tha twere embolised, some residue remained in 16 cases. Embolisation eliminated most of the associated vascular risk factors, as can be seen by the fact that associated risk factors disappeared in 28 (65%) out of the 43 AVM with such factors. The morbidity and mortality rates with embolisation were 8% and 2%, respectively. Conclusions. Embolisation eliminated most of the vascular risk factors, with complete obliteration in 27 cases and size was satisfactorily reduced for later treatment; at the same time, morbidity and mortality rates were acceptable (AU)
Assuntos
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Contexto em Saúde: ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis Problema de saúde: Doença Cardiovascular / Doença Cerebrovascular / Anomalias Congênitas e Cromossômicas Base de dados: IBECS Assunto principal: Malformações Arteriovenosas Intracranianas / Radiocirurgia / Embolização Terapêutica Tipo de estudo: Estudo de etiologia / Estudo prognóstico / Fatores de risco Limite: Adulto / Feminino / Humanos / Masculino Idioma: Espanhol Revista: Rev. neurol. (Ed. impr.) Ano de publicação: 2006 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Miguel Servet/España
Buscar no Google
Coleções: Bases de dados nacionais / Espanha Contexto em Saúde: ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis Problema de saúde: Doença Cardiovascular / Doença Cerebrovascular / Anomalias Congênitas e Cromossômicas Base de dados: IBECS Assunto principal: Malformações Arteriovenosas Intracranianas / Radiocirurgia / Embolização Terapêutica Tipo de estudo: Estudo de etiologia / Estudo prognóstico / Fatores de risco Limite: Adulto / Feminino / Humanos / Masculino Idioma: Espanhol Revista: Rev. neurol. (Ed. impr.) Ano de publicação: 2006 Tipo de documento: Artigo Instituição/País de afiliação: Hospital Miguel Servet/España
...